title: Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma.
abstract: OBJECTIVE
  To evaluate adjuvant modalities after curative resection for hepatocellular carcinoma using a meta-analysis of randomized and non-randomized controlled trials.
  
  
  METHODS
  In a first step, a meta-analysis of randomized controlled trials was carried out. Sensitivity analyses after inclusion of non-randomized controlled trials were performed. Four therapeutic modalities were evaluated: pre-operative transarterial chemotherapy, post-operative transarterial chemotherapy, systemic chemotherapy and a combination of systemic and transarterial chemotherapy.
  
  
  RESULTS
  Only post-operative transarterial chemotherapy improved survival significantly at 2 years [difference, 22.8%; confidence interval (CI), 8.6-36.9%; P = 0.002] and 3 years (difference, 27.6%; CI, 8.2-47.1%; P = 0.005), and decreased the probability of no recurrence at 1 year (difference, 28.8%; CI, 16.7-40.8%; P < 0.001), 2 years (difference, 27.6%; CI, 8.2-47.1%; P = 0.005) and 3 years (difference, 28%; CI, 8.2-47.9%; P = 0.006). In a sensitivity analysis after inclusion of non-randomized controlled trials, post-operative transarterial chemotherapy still improved survival at 1 year (difference, 9.6%; CI, 0.8-18.3%; P = 0.03), 2 years (difference, 13.5%; CI, 0.9-26%, P = 0.04) and 3 years (difference, 18%; CI, 7-28.9%; P < 0.001), and decreased the probability of no recurrence at 1 year (difference, 20.3%; CI, 7.7-33%; P = 0.002), 2 years (difference, 35%; CI, 21.4-46.3%; P < 0.001) and 3 years (difference, 34.5%; CI, 18.7-50.3%; P < 0.001).
  
  
  CONCLUSIONS
  Post-operative transarterial chemotherapy improved survival and decreased the cumulative probability of no recurrence. New randomized controlled trials evaluating this modality are required.
authors.affiliation: Service d'Hépatogastroentérologie, Hôpital Claude Hurriez, CHRU Lille, France. p-mathurin@chru-lille.fr
authors.forename: P
authors.initials: P
authors.lastname: Mathurin
authors.forename: B
authors.initials: B
authors.lastname: Raynard
authors.forename: S
authors.initials: S
authors.lastname: Dharancy
authors.forename: S
authors.initials: S
authors.lastname: Kirzin
authors.forename: D
authors.initials: D
authors.lastname: Fallik
authors.forename: F-R
authors.initials: FR
authors.lastname: Pruvot
authors.forename: D
authors.initials: D
authors.lastname: Roumilhac
authors.forename: V
authors.initials: V
authors.lastname: Canva
authors.forename: J-C
authors.initials: JC
authors.lastname: Paris
authors.forename: J-C
authors.initials: JC
authors.lastname: Chaput
authors.forename: S
authors.initials: S
authors.lastname: Naveau
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018849:Controlled Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D011182:Postoperative Care; D011300:Preoperative Care; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents